



August 27, 2026

Company name: Nippon Soda Co., Ltd.
Name of representative: Eiji Aga
Representative Director and President
(Securities code: 4041; TSE Prime Market)
Inquiries: Toyonobu Katagishi
Manager of General Affairs Dept.
(Telephone: +81-3-6366-1920)

Milestone Achievement under License Agreement with MabGenesis Inc.

Nippon Soda Co., Ltd. (hereinafter "the Company") is pleased to announce that a milestone has been achieved under the license agreement with MabGenesis Inc. (Head Office: Yokohama, Kanagawa, Japan; CEO: Katsuhiko Shinjo; hereinafter "MabGenesis"), as previously announced in the Company's disclosure dated April 28, 2026, titled "Acquisition of License for Therapeutic Antibody for Feline Inflammatory Diseases from MabGenesis Inc."

1. About MabGenesis Inc.

MabGenesis is a startup biopharmaceutical company engaged in the research and development of therapeutic monoclonal antibody drugs. The Company possesses the world's highest quality phage display antibody library (MOURA library) and provides high-quality monoclonal antibodies that are difficult to obtain using conventional technologies.

In September 2025, the company entered into a collaborative research agreement with MabGenesis for the development of novel monoclonal antibody therapeutics for dogs and cats. In March 2026, the Company further entered into a license agreement with MabGenesis for therapeutic antibodies for feline inflammatory diseases.

2. About the Milestone

Upon achievement of this milestone, the Company will make a milestone payment to MabGenesis as stipulated under the agreement. The agreement also provides for the possibility of additional milestone payments based on developmental progress, as well as sales royalties in the future.

3. Future Development

Under the Company's new medium-term business plan, "Brilliance through Chemistry Stage III"* (fiscal years ending March 2027 through March 2030), announced in May 2026, the Company's basic objective is to transform into its business portfolio that generates stable earnings through the creation of new value and solutions via new businesses. The medium-term business plan also establishes sales KPIs for new businesses, including Animal Health, as numerical targets for the fiscal year ending March 2030.



The achievement of this milestone represents an important step toward realizing the targets set forth in the medium-term business plan. In pursuit of the new business creation set forth in the medium-term business plan, the Company will continue to promote research and development toward the launch of antibody therapeutics for cats, contributing to the resolution of social issues related to animal healthcare.